linjc16/ctgov huggingface dataset:
Comparison of Hemodynamic Changes With Morphine Versus Esmolol During Induction of Anaesthesia

Study Overview
=================
Brief Summary
-----------------
Comparing hemodynamic changes with morphine versus esmolol as an adjuvant agent during induction of Anaesthesia

Detailed Description
-----------------
Comparing hemodynamic profile of patients during induction of General Anesthesia with intravenous morphine as an adjuvant drug versus Intravenous esmolol as an adjuvant agent,My aim is to study which drug has superior hemodynamic profile in terms of hemodynamic stability of patient requiring General Anesthesia.

Official Title
-----------------
Comparison of Hemodynamic Changes With Morphine Versus Esmolol as an Adjuvant Agent During Induction of Anaesthesia

Conditions
-----------------
Intubation Complication

Intervention / Treatment
-----------------
* Drug: Intravenous morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 2 patients presenting for elective surgery. Exclusion Criteria: Patients having major cardiac disease. Metastatic disease. Pregnant females. Those unwilling to be part of study.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Morphine group<br>Half of participants will be comprising of morphine group | Drug: Intravenous morphine<br>* Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation. The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.<br>* Other names: Intravenous esmolol;|
| Experimental: Esmolol group<br>Half of participants will be comprising of esmolol group | Drug: Intravenous morphine<br>* Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation. The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.<br>* Other names: Intravenous esmolol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure | Change in blood pressure between baseline value and post Intubation value will be measured in millimeter of mercury (mmHg). | 06 months | 
| Pulse rate | Change in pulse rate between baseline value and post intubation value will be measured per minute. | 06 months |
Examining Clinical Trial Participation for Small Cell Lung Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Clinical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future small cell lung cancer patients during clinical trials.

Official Title
-----------------
Studying Patient Experiences in Small Cell Lung Cancer Clinical Trials to Identify Influencing Factors

Conditions
-----------------
Small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. Participant has a diagnosis of small cell lung cancer. Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. Exclusion Criteria: Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. Pregnant or lactating woman Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a small cell lung cancer clinical study. |  | 3 months | 
| Number of small cell lung cancer patients who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
small cell lung cancer
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Study Overview
=================
Brief Summary
-----------------
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

Detailed Description
-----------------
Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo. The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.

Official Title
-----------------
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Conditions
-----------------
Geographic Atrophy

Intervention / Treatment
-----------------
* Drug: Tinlarebant
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes. Minimum BCVA is required in the study eye Exclusion Criteria: The presence of diabetic macular edema or macular disease in either eye. Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye. Uncontrolled diagnosed glaucoma in the study eye

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LBS-008, Tinlarebant<br> | Drug: Tinlarebant<br>* 5 mg tablet taken orally once a day<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo tablets for tinlarebant 5 mg prepared similarly.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size |  | From baseline to Month 24] | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure the change in best-corrected visual acuity (BCVA) as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale |  | From baseline to Month 24 | 
| To measure changes in the area and size of the inner/outer segment junction of photoreceptors by spectral domain optical coherence tomography (SD-OCT) |  | From baseline to Month 24 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
LBS-008, Tinlarebant, GA
Inter- and Intra-observer Variability in First-trimester Uterine Artery Doppler Measurements.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the inter- and intra-observer variability of first-trimester Uterine Artery Doppler ultrasound measurements in pregnancies between 11+0 and 13+0 weeks of gestation. Participants will undergo a measurement protocol (six sets of Doppler ultrasounds measurements of right and left uterine artery) performed alternately by two observers (sonographers or physicians who perform these ultrasounds frequently in clinical practice at the outpatient clinic).

Detailed Description
-----------------
Doppler ultrasound measurements are increasingly performed in clinical practice to detect high-risk pregnancies. First-trimester uterine artery Doppler measurement might be a potential predictor for the development of maternal hypertensive disorders later on in pregnancy. However, before implementing this measurement into clinical practice and prediction models, the test characteristics of this first-trimester Doppler measurements should be adequately studied. The objective is to assess the inter- and intra-observer variability of first-trimester uterine Doppler ultrasound measurements.

Official Title
-----------------
Inter- and Intra-observer Variability in First-trimester Uterine Artery Doppler Measurements.

Conditions
-----------------
Doppler Measurement of Uterine Artery

Intervention / Treatment
-----------------
* Diagnostic Test: Doppler ultrasound measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton pregnancy Gestational age from 11+0 weeks to 13+6 weeks Exclusion Criteria: Maternal age <18 years Inability to give informed consent Multiple pregnancy Abnormal fetal heart tracings Non-viable pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inter- and intra-observer variability of first-trimester Uterine artery Doppler ultrasound | The aim of this study is to investigate the inter- and intra-observer variability of first-trimester Uterine Artery Doppler ultrasound measurements, according to the TRUST-study criteria for reproducibility assessment and analysis. | Between 11 and 13 weeks of gestation. Measurements will take place during general appointments and will take an extra 2-3 minutes |
Chronic Pelvic Pain in Females and Males

Study Overview
=================
Brief Summary
-----------------
Pelvic pain is under-reported in healthy adults. Many patients with pelvic pain under-estimate the problem. Chronic pelvic pain can be managed properly, if diagnosed promptly. This is a quantitative analysis of prospective clinical data. It evaluates the management of pelvic pain in a cohort population, and analyzes the treatment outcome.

Detailed Description
-----------------
Pelvic pain is common, but under-reported in healthy adults. Pelvic pain is reported more commonly in women than in men. Many patients with pelvic pain under-estimate the severity of the problem. Chronic pelvic pain can be managed successfully, if diagnosed properly. Many combinations of multimodal analgesia and rehabilitation therapy may be safe and effective for pelvic pain. This study is a quantitative analysis of prospective clinical data. It is an evaluation of the prevalence and management of pelvic pain in a cohort population of chronic pain patients. This is an analysis of multimodal analgesia types, rehabilitation therapy types, treatment outcome, and complications.

Official Title
-----------------
Chronic Pelvic Pain Management in Female and Male Adult Patients

Conditions
-----------------
Pelvic Pain Syndrome, Sacroiliac Disorder, Piriformis Syndrome, Sacrococcygeal Disorder, Inguinal Hernia

Intervention / Treatment
-----------------
* Behavioral: Rehabilitation therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic pelvic pain Patients with sacroiliac pain Patients with inguinal pain Patients with coccygeal pain Patients with piriformis pain Exclusion Criteria: Patients with spinal pain Patients who had spine surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult chronic pain patients<br>Adult chronic pain patients with pelvic, inguinal or sacroiliac pain | Behavioral: Rehabilitation therapy<br>* Chronic pain rehabilitation therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score, objective measurement using the validated Numeric Pain Rating scale | Pain score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less pain, high scores indicate worse pain | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pelvic pain
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Study Overview
=================
Brief Summary
-----------------
This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied. In observational studies, only observations are made without specified advice or interventions. Advanced or recurrent solid tumor harboring an NTRK gene fusion is a rare type of solid cancer caused by specific changes in the genes called NTRK gene fusion, and which has spread to nearby tissues and/or lymph nodes or has returned. Due to this change in the gene, an altered protein known as a TRK fusion protein is made, which can cause cancer cells to grow and survive. The main purpose of this study is to learn more about NTRK gene fusion in people in Japan. To do this, researchers will collect information on the number or percentage of Japanese people with NTRK gene fusion in any solid tumor. The data will come from the national database called C-CAT. They will cover the period from June 2019 until January 2023. Besides this data collection, no further tests or examinations are planned, and no visits are required in this study.

Official Title
-----------------
A Retrospective Observational Study to Investigate the Prevalence of NTRK Gene Fusion Positive in Solid Tumor in Japan

Conditions
-----------------
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Intervention / Treatment
-----------------
* Other: No Drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with any solid tumor and genome profiling results Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with solid tumor and genome profiling results<br>Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database. | Other: No Drug<br>* Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of patients with NTRK gene fusions by patient characteristic categories, such as tumor types |  | Retrospective data analysis from June 2019 to the latest data available (planned end of February 2023) | 
| Distribution of cancer types in patients with NTRK fusion positive among all, adult and pediatric |  | Retrospective data analysis from June 2019 to the latest data available (planned end of February 2023) |
Clinical Trial of Biolimus-coated Intracranial Balloon Dilation Catheter

Study Overview
=================
Brief Summary
-----------------
This test took the target lesion restenosis rate 6 months after the operation as the main endpoint to verify the effectiveness of the intracranial balloon expansion catheter of Biolimus coating. After completing the follow-up 6 months after the operation, a clinical summary report was issued for the registration application of the product, and on this basis, 12 months of postoperative follow-up was carried out to evaluate the mid-term curative effect.

Official Title
-----------------
Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of Biolimus-coated Intracranial Balloon Dilation Catheter Treatment of Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Conditions
-----------------
Intracranial Atherosclerotic Stenosis

Intervention / Treatment
-----------------
* Device: Drug balloon dilated
* Device: balloon dilated


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 80 years old; Symptomatic intracranial artery stenosis, and the degree of visual stenosis of target blood vessels under intracranial angiography is 70 99%(WASID method); Exclusion Criteria: Target blood vessels are seriously calcified and distorted, and it is difficult to put the interventional instruments in place or recover; Ischemic cerebral infarction occurred 3 weeks before surgery; Cerebral hemorrhage 3 months before operation;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Ratio of control group to test group 1:1
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental group<br> | Device: Drug balloon dilated<br>* Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis<br>|
| Experimental: Control group<br> | Device: balloon dilated<br>* Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-month target lesion restenosis rate |  | 6-month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial balloon, stenosis
Airway Involvement In Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
To estimate prevalence of subclinical airway injuries among IBD patients. To investigate relationship between activity of IBD and airways

Detailed Description
-----------------
Airway diseases are the most commonly described lung manifestations of inflammatory bowel disease (IBD). However, the similarities in disease pathogenesis and the sharing of important environmental risk factors and genetic susceptibility suggest that there is a complex interplay between IBD and airway diseases.Extraintestinal manifestations (EIM) commonly occur in inflammatory bowel diseases (IBD), with a prevalence rate between 21%-41% reported in various series. Crohn's disease (CD) presents with EIM more frequently than ulcerative colitis (UC). Pulmonary involvement complicating IBD was originally considered rare (with a frequency rate < 1%), but the first case series published in 1976 assisted in better recognition, evaluation and description of IBD related respiratory disease. Pulmonary involvement is often asymptomatic and may be detected solely on the basis of abnormal screening tests. This review will focus on the involvement of the airways in the context of IBD. Although IBD related PM were originally considered rare, certain population-based studies have revealed significant interrelationships between the lungs and IBD. Bernstein and colleagues in a large population-based study in North America in 2005 reported that airway disorders in general (including asthma and bronchitis) were the most common extraintestinal manifestation in subjects with CD and the second most common in subjects with UC, with the prevalence of asthma in this population between 7%-8%. In another retrospective study from the opposite view, Birring reported that IBD was 4 times more prevalent among patients with airway diseases, particularly non-asthmatic patients with productive cough, than in the general population.

Official Title
-----------------
Spectrum Of Airway Involvement In Inflammatory Bowel Disease

Conditions
-----------------
IBD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients attended to IBD clinic at Tropical Department Exclusion Criteria: Age: less than 18 years Unstable patients or need for ICU admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictors of airway diseases in patients with IBD | FROM risk factors | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| -Prevalence of of subclinical airway injuries among IBD patients presented to Tropical Department in Assiut University Hospital | from statistical anyalasis | baseline |